Biohaven Pharmaceutical Holding (NYSE:BHVN) reported new data from its Phase 2/3 trial of rimegepant, and orally-dosed calcitonin gene-related peptide (CGRP) antagonist, for the prevention of migraines.
During the third month of scheduled dosing, nearly 50% of patients treated with rimegepant every other day experienced a 50% or greater reduction in the frequency of monthly moderate-to-severe migraine days.
The data also demonstrated that oral rimegepant is safe and effective for the treatment of breakthrough migraine attacks in patients taking injectable anti-CGRP monoclonal antibodies.
Rimegepant has met its primary endpoint in three pivotal Phase 3 trials and Biohaven expects to file an NDA for the drug in 2019.
